The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Idiosyncratic drug-induced liver injury (DILI) is a rare, serious and sometimes fatal condition that lacks an effective clinical countermeasure. Polymorphisms of bioactivation/toxification pathways via the Phase I drug-metabolizing enzymes, Phase II detoxification reactions and Phase III excretion/transport, together with immunological factors, are predisposing factors for some DILI. AREAS COVERED: This review focuses on the seminal role of hepatic drug metabolism in the idiosyncratic toxicity response and the potential role of genetic polymorphisms in specific drug-metabolizing enzymes or transporters. Furthermore, the article looks at recent developments for the assessment of those mechanisms, in order to avoid them in novel drug candidates that are still under development. Examples of proposed or confirmed metabolic mechanisms from the current literature for marketed or previously marketed drugs are summarized in detail. The contributions of Phase I, II and III and other enzymatic pathways in the idiosyncratic response are reviewed with particular emphasis on gene polymorphisms that might explain why some individuals respond in an aberrant manner. EXPERT OPINION: Toxicologists continue to focus their efforts to define the idiosyncratic response at the biochemical and molecular levels. This has resulted in the development of some early drug screening tools based on such characteristics as the daily dose, metabolite covalent binding and polymorphisms in drug-metabolizing enzymes. While it will take years to fully assess the impact of these recently developed assessment tools, research on genetically based differences in hepatic metabolic pathways will continue, aided by the establishment of DILI registries for improved patient access.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Daly, A. K., Aithal, G. P., Leathart, J. B. S., Swainsbury, R. A., Dang, T. S., & Day, C. P. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.023 · Cited by 348 · cited 1×
“Allelic variants of UGT2B7, CYP2C8 and ABCC2 (MRP2), which may lead to the formation of RMs, have been associated with diclofenac hepatotoxicity [97].”
BackgroundRisk Factors for Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., & Björnsson, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.001 · Cited by 347 · cited 3×
“For idiosyncratic DILI in adults, older age is more associated with cholestatic damage with male prominence [18], and hepatocellular DILI injury is more common among women as is DILI severity [19].”
BackgroundDawson, S., Stahl, S., Paul, N., Barber, J., & Kenna, J. G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040758 · Cited by 343
Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., & Baillie, T. A. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000180q · Cited by 311
Idiosyncratic drug-induced liver injury: an overview
Hussaini, S. H., & Farrington, E. A. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.6.673 · Cited by 183
Drug-induced liver injury: Is it somehow foreseeable?
Tarantino, G., Minno, M. N. D. D., & Capone, D. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2817 · Cited by 137
Drug-induced liver injury: a clinical update
Ghabril, M., Chalasani, N., & Björnsson, E. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283383c7c · Cited by 123 · cited 2×
“Not only are drugs with extensive hepatic metabolism associated with a higher frequency of idiosyncratic DILI, but also recent studies have revealed that this toxicity exhibits an important dose dependency [12].”
BackgroundFeng, B., Xu, J. J., Bi, Y.-A., Mireles, R., Davidson, R., Duignan, D. B., Campbell, S., Kostrubsky, V. E., Dunn, M. C., Smith, A. R., et al. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp033 · Cited by 80
Pachkoria, K., Lucena, M. I., Ruiz‐Cabello, F., Crespo, E., Cabello, M. R., Andrade, R. J., & on behalf of the Spanish Group for the Study of Drug‐Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos (GEHAM) (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707122 · Cited by 49 · cited 1×
“[100] have found no evidence to support CYP2C9 and CYP2C19 genetic polymorphisms as predictable risk factors in DILI.”
Background
Cited by
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Kostadinova, R., Boess, F., Applegate, D., Suter, L., Weiser, T., Singer, T., Naughton, B., & Roth, A. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.01.012 · Cited by 262
Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., Afshari, C. A., & Hamadeh, H. K. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft176 · Cited by 243
Liu, Y., Wang, W., Sun, M., Ma, B., Pang, L., Du, Y., Dong, X., Yin, X., & Ni, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01467 · Cited by 49
Metadata
- Authors
- Amacher, D. E.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa Healthcare
- Published
- 2012-01-31
- Volume
- 8
- Issue
- 3
- Pages
- 335-347
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2129260329
- Cited by
- 55
- References
- 9
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury. https://app.cochat.ai/papers/10.1517/17425255.2012.658041
- The paper
- Amacher, D. E. (2012). The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2012.658041
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.